There is no "one size fits all" in personalised medicine. In this episodes Andrew and Dr Donohoe explore some of the nuances affecting individual biochemistry.
SIBO causes inflammation both in the gut and systemically and is notoriously difficult to treat, with high relapse rates, so finding new treatment protocols for SIBO is hugely beneficial.
Abdominal pain is one of the most common diagnoses in hospitalised children and the leading symptom in child and adolescent GIT diseases. It is also a common symptom of SIBO.
A recent meta-analysis published in June of 2015 has shown that saccharomyces boulardii is an effective intervention in the reduction of risk of antibiotic associated diarrhoea (AAD) in both children and adults.
Saccharomyces boulardii (SB) is a beneficial probiotic, non-colonising yeast. It modulates the host’s innate gastrointestinal (GIT) immune response and improves GIT integrity.
Results from a new study suggest microbial diversity of the oral and intestinal mucosa in patients with acute myelogenous leukemia (AML) has a significant impact on the risk for infectious complication in the first three months of induction chemotherapy.